200 related articles for article (PubMed ID: 36227941)
1. Comprehensive analyses reveal the role of histone deacetylase genes in prognosis and immune response in low-grade glioma.
Shen L; Li Y; Li N; Shen L; Li Z
PLoS One; 2022; 17(10):e0276120. PubMed ID: 36227941
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of histone deacetylases genes in the prognosis and immune infiltration of glioma patients.
Shen L; Li Y; Li N; Shen L; Li Z
Aging (Albany NY); 2022 May; 14(9):4050-4068. PubMed ID: 35545840
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of HDAC Family Identifies
Fan Y; Peng X; Wang Y; Li B; Zhao G
Front Mol Biosci; 2021; 8():720020. PubMed ID: 34540896
[No Abstract] [Full Text] [Related]
4. Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer.
Hao L; Lu W; Wu J; Chen Y; Xu D; Wang P
Sci Rep; 2024 Apr; 14(1):8983. PubMed ID: 38637684
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study.
Zhou X; Ling Y; Cui J; Wang X; Long N; Teng W; Liu J; Xiang X; Yang H; Chu L
Sci Rep; 2024 Jun; 14(1):12602. PubMed ID: 38824202
[TBL] [Abstract][Full Text] [Related]
6. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
8. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis Identified Glycosyltransferase Signature to Predict Glioma Prognosis and TAM Phenotype.
Qi Y; Lv W; Liu X; Wang Q; Xing B; Jiang Q; Wang Z; Huang Y; Shu K; Lei T
Biomed Res Int; 2023; 2023():6082635. PubMed ID: 36685667
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
12. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of a new prognosis signature based on histone deacetylases in clear cell renal cell carcinoma.
Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Niu Z; He W
Cancer Med; 2021 Sep; 10(18):6503-6514. PubMed ID: 34308568
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a risk model and molecular subtypes based on tryptophan metabolism-related genes to predict the clinical prognosis and tumor immune microenvironment in lower-grade glioma.
Li W; Ling L; Xiang L; Ding P; Yue W
Front Cell Neurosci; 2023; 17():1146686. PubMed ID: 36925967
[TBL] [Abstract][Full Text] [Related]
15. The PANoptosis-related signature indicates the prognosis and tumor immune infiltration features of gliomas.
Song J; Xu Z; Fan Q; Sun Y; Lin X
Front Mol Neurosci; 2023; 16():1198713. PubMed ID: 37501725
[TBL] [Abstract][Full Text] [Related]
16. Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.
Li L; Yang Z; Zheng Y; Chen Z; Yue X; Bian E; Zhao B
BMC Neurol; 2022 May; 22(1):192. PubMed ID: 35614390
[TBL] [Abstract][Full Text] [Related]
17. A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma.
Luo H; Tao C; Long X; Huang K; Zhu X
Aging (Albany NY); 2021 Jun; 13(12):16198-16218. PubMed ID: 34114970
[TBL] [Abstract][Full Text] [Related]
18. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
Front Oncol; 2021; 11():650153. PubMed ID: 34055619
[TBL] [Abstract][Full Text] [Related]
20. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
